The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
News|Articles|September 1, 2026
Accelerating patient recruitment: Connecting the right patients to the right trial
Author(s)Quest Diagnostics
Advertisement
Discover how Quest Diagnostics puts its vast database of lab results to work and leverages patient and physician credibility to efficiently and effectively connect the best-fit patients to the clinical trials that will benefit from their participation.
This white paper is free and can be downloaded and read at your convenience.
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Advertisement
Advertisement
Trending on PharmExec
1
The US Drug-Pricing Reset: Competing on Net Value
2
Novo Terminates Research Collaboration With Korro Bio
3
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
4
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
5